Clinical Trials Browser

Phase 3 × Active not recruiting × Sunitinib × Clear all

NCT05043090 2026-05-22

SAMETA

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Phase 3 Active not recruiting

GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT03768063 2026-04-28

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT03673501 2026-02-05

INTRIGUE

Phase 3 Active not recruiting

453 enrolled 20 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05734105 2025-12-17

INSIGHT

Phase 3 Active not recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT04523272 2024-10-15

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Phase 3 Active not recruiting

Advanced Renal Cancer